Endogena Therapeutics, Inc.
Endogenous regenerative medicine therapeutics that activate the body's innate repair mechanisms for degenerative diseases
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2016
- Latest Form D
- $7.3M, Nov 2021
- Total capital
- $15.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $15.3M
- 2 Form D · last Nov 2021
- 59 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 6 pending · first 2020
- Rank in peer group#245 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$7.3M
- Private capital raisedForm D · SEC · 1st filing$8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Matthias StegerResearcherExecutive Officer, DirectorLinked by 6 patents
- Aaron WeaverDirectorNamed in SEC Form D filings
- Daniel ZabrowskiDirectorNamed in SEC Form D filings
- Dirk HarbeckeDirectorNamed in SEC Form D filings
- Elona BaumDirectorNamed in SEC Form D filings
- Markus BertiniExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 12- GrantedNew Compounds And Their Use As Therapeutically Active Substances In The Treatment And/or Prevention Of Diseases Involving The Retinal Pigment EpitheliumUSPTOUS 12,630,542
- GrantedN-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE Derivatives And Related Compounds As Stimulators Of The Production Of Retinal Precursor Cells For The Treatment Of Neuroretinal DiseasesUSPTOUS 12,195,452
- GrantedNew Compounds And Their Use As Therapeutically Active Substances In The Treatment And/or Reducing Signs Or Symptoms Of Diseases Involving The Retinal Pigment EpitheliumUSPTOUS 11,844,755
Show all 12 patent records
- New Compounds And Their Use As Therapeutically Active Substances In The Treatment And/or Prevention Of Diseases Involving The Retinal Pigment EpitheliumMay 19, 2026 · US 12,630,542Granted
- N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE Derivatives And Related Compounds As Stimulators Of The Production Of Retinal Precursor Cells For The Treatment Of Neuroretinal DiseasesJan 14, 2025 · US 12,195,452Granted
- New Compounds And Their Use As Therapeutically Active Substances In The Treatment And/or Reducing Signs Or Symptoms Of Diseases Involving The Retinal Pigment EpitheliumDec 19, 2023 · US 11,844,755Granted
- New Compounds And Their Use As Therapeutically Active Substances In The Treatment And/or Prevention Of Diseases Involving The Retinal Pigment EpitheliumNov 16, 2023 · Application 18030917Pending
- New Compounds And Their Use As Therapeutically Active Substances In The Treatment And/or Reducing Signs Or Symptoms Of Diseases Involving The Retinal Pigment EpitheliumJan 3, 2023 · US 11,541,039Granted
- Compounds For Use As Therapeutically Active Substances In The Treatment And/or Prevention Of Neuroretinal DiseasesMar 24, 2022 · Application 17418057Pending
- Compounds For Use As Therapeutically Active Substances In The Treatment Of Retinal DiseasesOct 20, 2020 · US 10,807,973Granted
- Compounds For Use As Therapeutically Active Substances In The Treatment Of Retinal DiseasesAug 25, 2020 · US 10,752,593Granted
- Compounds For Use As Therapeutically Active Substances In The Treatment And/or Prevention Of Neuroretinal DiseasesApplication PCTUS2019068768Pending
- Compounds For Use As Therapeutically Active Substances In The Treatment And/or Prevention Of Neuroretinal DiseasesApplication PCTUS2019068759Pending
- New Compounds And Their Use As Therapeutically Active Substances In The Treatment And/or Prevention Of Diseases Involving The Retinal Pigment EpitheliumApplication PCTUS2021053577Pending
- New Compounds And Their Use As Therapeutically Active Substances In The Treatment And/or Prevention Of Diseases Involving The Retinal Pigment EpitheliumApplication PCTUS2020038715Pending
Related companies, and why
- Clene Inc.Similar federal contract value in Biotech · null in contracts
- Icagen-T, Inc.Similar federal contract value in Biotech · null in contracts
- Ankasa Regenerative Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SystImmune, Inc.Similar federal contract value in Biotech · null in contracts
- Paragon Biosciences Qlarity Capital, Inc.Similar federal contract value in Biotech · null in contracts
- DoubleRainbow Biosciences Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .